WO2006038217A1 - An improved drug delivery system of citalopram hydrobromide and process for producing the same - Google Patents
An improved drug delivery system of citalopram hydrobromide and process for producing the same Download PDFInfo
- Publication number
- WO2006038217A1 WO2006038217A1 PCT/IN2004/000308 IN2004000308W WO2006038217A1 WO 2006038217 A1 WO2006038217 A1 WO 2006038217A1 IN 2004000308 W IN2004000308 W IN 2004000308W WO 2006038217 A1 WO2006038217 A1 WO 2006038217A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delivery system
- drug delivery
- pellets
- capsule
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Definitions
- This invention in general relates to an improved drug delivery system of Citalopram hydrobromide and process for producing the same. More particularly the invention provides for devising pellets formulation of Citalopram hydrobromide and disposing the same into a capsule and a process for producing the same.
- Citalopram hydrobromide belongs to a general class of antianxiety and antidepressant drugs. It is highly selective and potent serotonin reuptake inhibitor with minimal effects on the neuronal reuptake of norepinephrine and dopamine. The ability of citalopram to potentiate serotonergic activity in the central nervous system via inhibition of the neuronal reuptake of serotonin is thought to be responsible for its antidepressant action.
- the prior art discloses many systems for the delivery of citalopram hydrobromide such as film-coated tablets, hard gelatin capsules, sustained release tablets etc.
- WO 01/22941A1 discloses melt granulated composition and modified release dosage form prepared from said composition by one (or) more hydrophilic cellulose other polymers or a hydrophilic melt binder and (or) a therapeutically active ingredient.
- NAD 299 a second component (b) which is citalopram, as the racemate or an enantiomer thereof in the form of its free base, or a pharmaceutically acceptable salt and/or solvate thereof, the preparation thereof, pharmaceutical formulations containing said composition, use of and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition as well as a kit containing said composition.
- tablets or capsules are generally made either by granulation method or direct compression method. In both the methods, the dust generation during the process is very high. Being a potent drug, even in low dosage, exposure for longer period may cause unnecessary side effects for the people who are working in the manufacturing of the medicament.
- an improved drug delivery system wherein the system comprises pellets of Citalopram hydrobromide disposed into a capsule whereby the system enables better bioavailability due to homogeneous distribution of the drug.
- a process for producing pellets of citalopram hydrobromide comprises, solubilising Citalopram hydrobromide in a mixture of isopropyl alcohol and water to make a homogeneous solution and stirring the same for 10 to 15 minutes after adding fillers, binders, glidants, plastcizers and spraying uniformly on neutral pellets. This provides better content uniformity than conventional dosage forms and avoids dust generation.
- Another embodiment of the present invention provides a process for producing pellets of citalopram hydrobromide, wherein the process comprises mixing Citalopram hydrobromide with suitable excipients like fillers, binders, glidants, plastcizers, and passing the same through spheronizer to form pellets.
- a process for producing sustained release pellets of citalopram hydrobromide comprising mixing Citalopram hydrobromide with suitable excipients and passing the same through spheronizer to make pellets and coating the pellets with suitable polymer, selected from a group comprising, hydroxy propyl methyl cellulose, cellulose derivatives, methacrylic acid copolymer, ethyl cellulose, sodium alginate, guar gum, xanthan gum, carbopol, alginate derivative or a mixture thereof, to get desired drug release profile.
- suitable polymer selected from a group comprising, hydroxy propyl methyl cellulose, cellulose derivatives, methacrylic acid copolymer, ethyl cellulose, sodium alginate, guar gum, xanthan gum, carbopol, alginate derivative or a mixture thereof, to get desired drug release profile.
- an improved drug delivery system wherein the pellets formed by the above process are disposed in a capsule.
- the present invention aims at providing an improved drug delivery system and process for producing the same.
- the system is a capsule, which contains pellets form of citalopram hydrobromide.
- the capsule disclosed in the invention can be any kind of capsule like hard gelatin or soft gelatin capsule.
- the pellets used for filling in the capsules are immediate release pellets or sustained release pellets.
- the pellets, which are to be sprayed with the active substance can be neutral pellets.
- the quantity of the pellets is not essential for the present invention and may vary between approximately 20 to 88%.
- the pellets coated with active substance are produced by dissolving the active in a solubiliser and mixing with other pharmaceutically acceptable excipients, which include fillers, binders, glidants, plastcizers etc. and spraying on non-pareil seeds. Pellet layering is done by spray coating/layering equipment.
- the active substance Before the pellets are sprayed, the active substance may be mixed with further components.
- Such components can be filler, binder, glidants, plastcizers, alone or in mixtures.
- the solubiliser used in the present invention is selected from a group comprising, Isopropyl alcohol, ethanol, methylene chloride, purified water, acetone or mixture thereof.
- the percentage range of solubiliser is varied from 10 to 90%.
- the surface area of the drug is increased to a large extent in comparison to other oral dosage forms because fine particles of drug are coated on pellets due to which solubility of the drug increases.
- the diluents / filler used in the invention can be selected from the group comprising, cellulose derivatives, lactose, maize starch, modified starch, pregelatinised starch, partially hydrolysed starch, calcium salts, magnesium salts, maltodextrin, sorbitol, mannitol, sucrose, mannose etc. Concentration of the diluents / fillers can vary from 1.0 to 75%.
- Plasticizers used in the invention are selected from the group comprising, triacetin, polyetheylene glycol, propylene glycol, diethyl phthalate, castor oil alone or mixture thereof.
- concentration of the plasticizers can vary from 0.1 to 38%.
- the binder used in the invention is selected from starch derivatives, Povidone, gelatin.
- the concentration of the binder can range from 0.5 % to 20%.
- Another process to prepare a pellet of citalopram hydrobromide comprises, mixing citalopram hydrobromide with suitable pharmaceutical excipients disclosed above and passing through a spheronizer to form immediate release pellets which can be encapsulated in a capsule to provide improved drug delivery system.
- pellets form containing citalopram hydrobromide are coated with suitable polymers to achieve desired release profile.
- the polymer used is selected from a group comprising hydroxy propyl methyl cellulose, cellulose derivatives, Methacrylic acid copolymer, ethyl cellulose, sodium alginate, guar gum, xanthan gum, carbopol, alginate derivative, alone or in combination thereof.
- the concentration of the polymers can vary from 2.0 to 65.0%.
- the most preferred polymer is ethyl cellulose.
- the viscosity of the ethyl cellulose can vary from 5 cps to 100 cps.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed herein is an improved drug delivery system of citalopram hydrobromide and process for producing the same. The drug delivery system comprises a pellet formulation of said drug filled in a capsule.
Description
AN IMPROVED DRUG DELIVERY SYSTEM OF CITALOPRAM HYDROBROMIDE AND PROCESS FOR PRODUCING THE SAME
Field of the Invention
This invention in general relates to an improved drug delivery system of Citalopram hydrobromide and process for producing the same. More particularly the invention provides for devising pellets formulation of Citalopram hydrobromide and disposing the same into a capsule and a process for producing the same.
Background of the Invention
Citalopram hydrobromide belongs to a general class of antianxiety and antidepressant drugs. It is highly selective and potent serotonin reuptake inhibitor with minimal effects on the neuronal reuptake of norepinephrine and dopamine. The ability of citalopram to potentiate serotonergic activity in the central nervous system via inhibition of the neuronal reuptake of serotonin is thought to be responsible for its antidepressant action.
The prior art discloses many systems for the delivery of citalopram hydrobromide such as film-coated tablets, hard gelatin capsules, sustained release tablets etc.
International Application WOOl /80619 A2 discloses a solid unit dosage form comprising citalopram, which is prepared by direct compression of a mixture of citalopram base or a salt and excipients, or by filling of the mixture in a hard gelatin capsule. Large crystals of a pharmaceutical salt of citalopram and method for the manufacture of large crystals are also disclosed.
International Application WO02/053133 Al discloses a solid unit dosage form containing citalopram prepared by a process in which the citalopram base or its salt and excipients (binder and filler) is mixed by conventional mixing and is compacted on a roller compactor.
In international publication number WO 01/22941A1 discloses melt granulated composition and modified release dosage form prepared from said composition by one
(or) more hydrophilic cellulose other polymers or a hydrophilic melt binder and (or) a therapeutically active ingredient.
International Application WO 00/015219 discloses a pharmaceutical composition comprising a first component (a) which is (R)-3- N,N-dicyclobutylamino-8-fluoro-3,4- dihydro-2-H- 1 -benzopyran-5-carboxamide hydrogen-(2R,3R)-tartrate monohydrate
(NAD 299) and a second component (b) which is citalopram, as the racemate or an enantiomer thereof in the form of its free base, or a pharmaceutically acceptable salt and/or solvate thereof, the preparation thereof, pharmaceutical formulations containing said composition, use of and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition as well as a kit containing said composition.
However, tablets or capsules are generally made either by granulation method or direct compression method. In both the methods, the dust generation during the process is very high. Being a potent drug, even in low dosage, exposure for longer period may cause unnecessary side effects for the people who are working in the manufacturing of the medicament.
There was, therefore, a need to develop an improved pharmaceutical delivery device which could avoid the limitations present in the prior art like dust generation during manufacturing, film coating etc.
Summary of the Invention
In accordance with one preferred embodiment of the present invention, there is provided an improved drug delivery system wherein the system comprises pellets of Citalopram hydrobromide disposed into a capsule whereby the system enables better bioavailability due to homogeneous distribution of the drug.
In accordance with another embodiment of the present invention, there is provided a process for producing pellets of citalopram hydrobromide. The process comprises, solubilising Citalopram hydrobromide in a mixture of isopropyl alcohol and water to make a homogeneous solution and stirring the same for 10 to 15 minutes after adding
fillers, binders, glidants, plastcizers and spraying uniformly on neutral pellets. This provides better content uniformity than conventional dosage forms and avoids dust generation.
Another embodiment of the present invention provides a process for producing pellets of citalopram hydrobromide, wherein the process comprises mixing Citalopram hydrobromide with suitable excipients like fillers, binders, glidants, plastcizers, and passing the same through spheronizer to form pellets.
In accordance with yet another embodiment of the present invention, there is provided a process for producing sustained release pellets of citalopram hydrobromide, wherein the process comprises mixing Citalopram hydrobromide with suitable excipients and passing the same through spheronizer to make pellets and coating the pellets with suitable polymer, selected from a group comprising, hydroxy propyl methyl cellulose, cellulose derivatives, methacrylic acid copolymer, ethyl cellulose, sodium alginate, guar gum, xanthan gum, carbopol, alginate derivative or a mixture thereof, to get desired drug release profile.
in accordance with yet another embodiment of the present invention, there is provided an improved drug delivery system wherein the pellets formed by the above process are disposed in a capsule.
Detailed Description of the Invention
The present invention aims at providing an improved drug delivery system and process for producing the same. According to the preferred embodiment the system is a capsule, which contains pellets form of citalopram hydrobromide.
The capsule disclosed in the invention can be any kind of capsule like hard gelatin or soft gelatin capsule.
The pellets used for filling in the capsules are immediate release pellets or sustained release pellets.
The pellets, which are to be sprayed with the active substance, can be neutral pellets. The quantity of the pellets is not essential for the present invention and may vary between approximately 20 to 88%. The pellets coated with active substance are produced by dissolving the active in a solubiliser and mixing with other pharmaceutically acceptable excipients, which include fillers, binders, glidants, plastcizers etc. and spraying on non-pareil seeds. Pellet layering is done by spray coating/layering equipment.
Before the pellets are sprayed, the active substance may be mixed with further components. Such components can be filler, binder, glidants, plastcizers, alone or in mixtures.
The solubiliser used in the present invention is selected from a group comprising, Isopropyl alcohol, ethanol, methylene chloride, purified water, acetone or mixture thereof. The percentage range of solubiliser is varied from 10 to 90%.
In the present invention the surface area of the drug is increased to a large extent in comparison to other oral dosage forms because fine particles of drug are coated on pellets due to which solubility of the drug increases.
The diluents / filler used in the invention, can be selected from the group comprising, cellulose derivatives, lactose, maize starch, modified starch, pregelatinised starch, partially hydrolysed starch, calcium salts, magnesium salts, maltodextrin, sorbitol, mannitol, sucrose, mannose etc. Concentration of the diluents / fillers can vary from 1.0 to 75%.
Plasticizers used in the invention are selected from the group comprising, triacetin, polyetheylene glycol, propylene glycol, diethyl phthalate, castor oil alone or mixture thereof. The concentration of the plasticizers can vary from 0.1 to 38%.
The binder used in the invention is selected from starch derivatives, Povidone, gelatin. The concentration of the binder can range from 0.5 % to 20%.
Another process to prepare a pellet of citalopram hydrobromide comprises, mixing
citalopram hydrobromide with suitable pharmaceutical excipients disclosed above and passing through a spheronizer to form immediate release pellets which can be encapsulated in a capsule to provide improved drug delivery system.
To prepare sustained release formulations of citalopram hydrobromide, pellets form containing citalopram hydrobromide are coated with suitable polymers to achieve desired release profile. The polymer used is selected from a group comprising hydroxy propyl methyl cellulose, cellulose derivatives, Methacrylic acid copolymer, ethyl cellulose, sodium alginate, guar gum, xanthan gum, carbopol, alginate derivative, alone or in combination thereof. The concentration of the polymers can vary from 2.0 to 65.0%.
The most preferred polymer is ethyl cellulose. The viscosity of the ethyl cellulose can vary from 5 cps to 100 cps.
Examplel
Citalopram Hydrobromide capsules
Citalopram Hydrobromide capsules SR
While this invention has been described in detail with reference to certain preferred embodiments, it should be appreciated that the present invention is not limited to those precise embodiments. Rather, in view of the present disclosure, which describes the current best mode for practicing the invention, many modifications and variations would present themselves to those skilled in the art without departing from the scope and spirit of this invention.
Claims
1. An improved drug delivery system comprising: pellets of citalopram hydrobromide filled in a capsule, wherein the pellets are spray coated and administrable as immediate release pellets or sustained release pellets.
2. The drug delivery system according to claim 1, wherein citalopram hydrobromide is about 2-60% w/w.
3. The drug delivery system according to claim 1, wherein said capsule is soft gelatin capsule or hard gelatin capsule.
4. The drug delivery system according to claim 1, wherein quantity of pellets vary from 20 to 88% per capsule.
5. The drug delivery system according to claim 1, wherein said spray coated pellets are coated with homogeneous solution of citalopram hydrobromide.
6. The drug delivery system according to claim 5, wherein the pellets are produced by solubilizing citalopram hydrobromide in a mixture of solubilizing agents, adding fillers, binders, glidants, plastcizers in the mixture and spraying uniformly on neutral pellets.
7. The drug delivery system according to claim 6, wherein the solubilising agent is selected from a group comprising isopropyl alcohol, ethanol, methylene chloride, purified water, acetone or a mixture thereof.
8. The drug delivery system according to claim 7, wherein the concentration of solubilizing agent is about 10 to 90%.
9. The drug delivery system according to claim 1, wherein said immediate release pellets are produced by mixing the drug with fillers, binders, glidants, plastcizers and passing the same through spheronizer to form pellets.
10. The drug delivery system according to claim 1, wherein said sustained release pellets are produced by mixing the drug with fillers, binders, glidants, plastcizers, passing the mixture through spheronizer to form pellets and coating the pellets with suitable polymer.
11. The drug delivery system according to claim 10, wherein suitable polymer used for sustained release is selected from a group comprising, hydroxy propyl methyl cellulose, cellulose derivatives, methacrylic acid copolymer, ethyl cellulose, sodium alginate, guar gum, xanthan gum, carbopol, alginate derivative or a mixture thereof.
12. The drug delivery system according to claim 11, wherein the concentration of the polymers is about 2.0 to 65.0%.
13. The drug delivery system according to claim 11, wherein the polymer is hydroxy propyl methyl cellulose.
14. The drug delivery system according to claim 13, wherein the viscosity of hydroxy propyl methyl cellulose vary from 5 cps to 100000 cps.
15. The drug delivery system according to claim 11, wherein the polymer is ethyl cellulose.
16. The drug delivery system according to claim 15, wherein the viscosity of ethyl cellulose vary from 5 cps to 100 cps.
17. The drug delivery system according to any of claims 6, 9 or 10, wherein said filler is selected from a group comprising, cellulose derivative, lactose, maize starch, modified starch, pregelatinised starch, partially hydrolysed starch, calcium salts, magnesium salts, maltodextrin, sorbitol, mannitol, sucrose, mannosβ.
18. The drug delivery system according to claim 17, wherein the concentration of filler is about 1.0 to 75%.
19. The drug delivery system according to any of claims 6, 9 or 10, wherein said plasticizer is selected from a group comprising, triacetin, polyetheylene glycol, propylene glycol, diethyl phthalate, castor oil or a mixture thereof.
20. The drug delivery system according to claim 19, wherein the concentration of plasticizer is about 0.1 to 38%.
21. The drug delivery system according to any of claims 6, 9 or 10, wherein said binder is selected from a group comprising, starch derivatives, Povidone, gelatin.
22. The drug delivery system according to claim 21, wherein the concentration of binder is about 0.5 to 20%.
23. A process for producing an improved drug delivery system, the process comprising, solubilising citalopram hydrobromide in a solubilising agent to make a homogeneous solution, stirring the same for 10 to 15 minutes after adding filler, binder, glidants, plastcizers and spraying uniformly on neutral pellets and filling the coated pellets in a capsule.
24. The drug delivery system according to claim 23, wherein the solubilising agent is selected from a group comprising, isopropyl alcohol, ethanol, methylene chloride, purified water, acetone or a mixture thereof.
25. The drug delivery system according to claim 24, wherein the concentration of solubilising agent is about 10 to 90%.
26. The process according to claim 23, wherein the capsule is soft gelatin capsule or hard gelatin capsule.
27. The process according to claim 23, wherein the quantity of pellets vary from 20 to 88% per capsule.
28. A process for producing an improved drug delivery system, the process comprising, mixing citalopram hydrobromide with filler, binder, glidants, plastcizers, passing the same through spheronizer to form pellets and filling the pellets thus formed in a capsule.
29. The process according to claim 28, wherein the capsule is soft gelatin capsule or hard gelatin capsule.
30. The process according to claim 28, wherein the quantity of pellets vary from 20 to 88% per capsule.
31. A process for producing an improved drug delivery system, the process comprising, mixing citalopram hydrobromide with filler, binder, glidants, plastcizers, passing the same through spheronizer to form pellets, coating the pellets with suitable polymer to form sustained release pellets and filling said pellets in a capsule.
32. The process according to claim 31, wherein the capsule is soft gelatin capsule or hard gelatin capsule.
33. The process according to claim 31, wherein the quantity of pellets vary from 20 to 88% per capsule.
34. The process according to claim 31, wherein the suitable polymer used for sustained release is selected from a group comprising, hydroxy propyl methyl cellulose, cellulose derivative, methacrylic acid copolymer, ethyl cellulose, sodium alginate, guar gum, xanthan gum, carbopol, alginate derivative or a mixture thereof.
35. The process according to claim 34, wherein the concentration of polymer is about 2.0 to 65.0%.
36. The process according to claim 34, wherein the polymer is hydroxy propyl methyl cellulose.
37. The process according to claim 36, wherein the viscosity of hydroxy propyl methyl cellulose vary from 5 cps to 100000 cps.
38. The process according to claim 34, wherein the polymer is ethyl cellulose.
39. The process according to claim 38, wherein the viscosity of ethyl cellulose vary from 5 cps to 100 cps.
40. The process according to any of claims 23, 28 or 31, wherein said filler is selected from a group comprising, cellulose derivative, lactose, maize starch, modified starch, pregelatinised starch, partially hydrolysed starch, calcium salts, magnesium salts, maltodextrin, sorbitol, mannitol, sucrose, mannose.
41. The process according to claim 40, wherein the concentration of filler is about 1.0 to 75%.
42. The process according to any of claims 23, 28 or 31, wherein said plasticizer is selected from a group comprising, triacetin, polyetheylene glycol, propylene glycol, diethyl phthalate, castor oil or mixture thereof.
43. The process according claim 42, wherein the concentration of plasticizer is about 0.1 to 38%.
44. The process according to any of claims 23, 28 or 31, wherein said binder is selected from a group comprising, starch derivatives, Povidone, gelatin.
45. The process according to claim 44, wherein the concentration of binder is about 0.5 to 20%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2004/000308 WO2006038217A1 (en) | 2004-10-05 | 2004-10-05 | An improved drug delivery system of citalopram hydrobromide and process for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2004/000308 WO2006038217A1 (en) | 2004-10-05 | 2004-10-05 | An improved drug delivery system of citalopram hydrobromide and process for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006038217A1 true WO2006038217A1 (en) | 2006-04-13 |
Family
ID=36142335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2004/000308 Ceased WO2006038217A1 (en) | 2004-10-05 | 2004-10-05 | An improved drug delivery system of citalopram hydrobromide and process for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006038217A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019074464A3 (en) * | 2017-10-09 | 2019-05-31 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 |
| CN120361104A (en) * | 2025-06-27 | 2025-07-25 | 杭州胡庆余堂药业有限公司 | Application of traditional Chinese medicine composition in preparation of medicines for preventing or treating colonitis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015219A1 (en) * | 1998-09-16 | 2000-03-23 | Astrazeneca Ab | A new composition |
| WO2001080619A2 (en) * | 2000-08-10 | 2001-11-01 | H. Lundbeck A/S | Pharmaceutical composition containing citalopram |
-
2004
- 2004-10-05 WO PCT/IN2004/000308 patent/WO2006038217A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015219A1 (en) * | 1998-09-16 | 2000-03-23 | Astrazeneca Ab | A new composition |
| WO2001080619A2 (en) * | 2000-08-10 | 2001-11-01 | H. Lundbeck A/S | Pharmaceutical composition containing citalopram |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019074464A3 (en) * | 2017-10-09 | 2019-05-31 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 |
| CN120361104A (en) * | 2025-06-27 | 2025-07-25 | 杭州胡庆余堂药业有限公司 | Application of traditional Chinese medicine composition in preparation of medicines for preventing or treating colonitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511510A (en) | Sustained release venlafaxine formulation | |
| CN101267819B (en) | A combination of long-acting and fast-acting sleeping pills | |
| US20110189269A1 (en) | Extended release composition containing tramadol | |
| CN1607947A (en) | Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol | |
| JP7227896B2 (en) | Pulsatile drug delivery system for treating morning immobility | |
| JP2010530422A (en) | Combination therapy for depression | |
| HUP0000759A2 (en) | Dosage forms containing R- and S-enantiomers in separate portions | |
| KR20050075408A (en) | Controlled release preparations comprising tramadol and topiramate | |
| US8968778B2 (en) | Threo-DOPS controlled release formulation | |
| SK6472000A3 (en) | Spheroid core, spheroid with its content, pharmaceutical composition comprising them and method for their producing | |
| US20090269402A1 (en) | Modified release composition of at least one form of venlafaxine | |
| US20150079187A1 (en) | Fixed dose combination therapy of parkinson's disease | |
| MXPA06003125A (en) | Modafinil modified release pharmaceutical compositions. | |
| JP2006528604A5 (en) | ||
| JP2006528604A (en) | An active substance sustained-release pharmaceutical comprising 6-dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclohexane-1,3-diol | |
| EP1928424B1 (en) | Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof | |
| JP2005537240A (en) | Spherical pellet containing active ingredients soluble in water | |
| WO2013186311A1 (en) | Extended release formulations | |
| WO2006038217A1 (en) | An improved drug delivery system of citalopram hydrobromide and process for producing the same | |
| US20150037405A1 (en) | Pharmaceutical compositions of levodopa and carbidopa | |
| US8158149B2 (en) | Threo-DOPS controlled release formulation | |
| US20080014261A1 (en) | Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction | |
| JP2006523633A (en) | Pharmaceutical composition comprising levodopa and carbidopa | |
| WO2007048080A2 (en) | Stable pharmaceutical formulations containing escitalopram and bupropion | |
| CN116920101A (en) | A new drug combination for the treatment of major depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 04817652 Country of ref document: EP Kind code of ref document: A1 |